Search research articles
Contact Us
Filters
Showing results (111-120 of 136) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
John M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Reproductive Biomedicine Online
|
March 12, 2017
Multi-centre assessment of nitroblue tetrazolium reactivity in human semen as a potential marker of oxidative stress
Jaime Gosálvez, Lamberto Coppola, Jose Luis Fernández, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 2, 2011
Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates
Willmen Youngsaye, Benjamin Vincent, Cathy L Hartland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
Chee Khoon Lee, Lucy Davies, Val J Gebski, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 23, 2015
Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake
Chris Dockendorff, Patrick W Faloon, Jun Pu, et al.
Molecular Cancer Therapeutics
|
June 28, 2015
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Ricardo Ribas, Sunil Pancholi, Stephanie K Guest, et al.
Breast Cancer Research and Treatment
|
September 20, 2019
Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience
Nicolò Matteo Luca Battisti, Victoria True, Narda Chaabouni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
Stephen Johnston, John Pippen, Xavier Pivot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 136) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy
John M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.
Reproductive Biomedicine Online
|
March 12, 2017
Multi-centre assessment of nitroblue tetrazolium reactivity in human semen as a potential marker of oxidative stress
Jaime Gosálvez, Lamberto Coppola, Jose Luis Fernández, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 2, 2011
Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates
Willmen Youngsaye, Benjamin Vincent, Cathy L Hartland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer
Chee Khoon Lee, Lucy Davies, Val J Gebski, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 23, 2015
Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake
Chris Dockendorff, Patrick W Faloon, Jun Pu, et al.
Molecular Cancer Therapeutics
|
June 28, 2015
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Ricardo Ribas, Sunil Pancholi, Stephanie K Guest, et al.
Breast Cancer Research and Treatment
|
September 20, 2019
Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience
Nicolò Matteo Luca Battisti, Victoria True, Narda Chaabouni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
Stephen Johnston, John Pippen, Xavier Pivot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer
Matthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Page
of 14